Natixis Advisors
SLXP

Natixis Advisors’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Natixis Advisors’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,680
Closed -$207K – 1303
2014
Q2 		$207K Buy
+1,680
New +$186K ﹤0.01% 1278
2013
Q4 		– Sell
-4,064
Closed -$272K – 1196
2013
Q3 		$272K Buy
4,064
+644
+19% +$44.4K 0.01% 1000
2013
Q2 		$226K Buy
+3,420
New +$196K ﹤0.01% 995

Other funds holding SLXP

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Natixis Advisors's SLXP Position: Q3 2014 in Review

Natixis Advisors sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q3 2014, closing a stake of 1,680 shares — an estimated $207K sold.

Natixis Advisors first reported a position in SLXP in Q2 2013 and held it in 3 quarters. The position peaked at $272K in Q3 2013. 348 funds tracked by Wall St. Rank hold SLXP as of Q3 2014.

  • Natixis Advisors reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q3 2014 after selling out during the quarter.
  • Natixis Advisors sold 1,680 SALIX PHARMACEUTICALS LTD DEL shares in Q3 2014, an estimated $207K.
  • Natixis Advisors first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 3 quarters.
  • Natixis Advisors's SALIX PHARMACEUTICALS LTD DEL position peaked at $272K in Q3 2013.
  • 348 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q3 2014.

Based on Natixis Advisors's 13F filing for Q3 2014, filed 3 Nov 2014.